
ABSTRACT OF THE DISCLOSURE

The invention relates to antibodies which bind to the CD23 (FC ϵ RII) type II molecule particularly altered antibodies including antibodies which bind to the CD23 (FC ϵ RII) type II molecule characterized by an affinity constant equal to or greater than $1 \times 10^9 \text{ Ka Mol}^{-1}$, the preparation of such antibodies, pharmaceutical compositions which contain such antibodies and their use in therapy particularly in the treatment of autoimmune and inflammatory disorders.

03
